C. diff Risk


Oral Bioavailability


Approximate Cost



1 g IV q24h

CrCl >50 ml/min

  • 1g IV Q24h

CrCl <30 ml/min

  • 500 mg IV Q24h

Dialysis (HD or CRRT)

  • 500mg IV Q24h

15 mg/kg/dose Q12H
Maximum: 1g/dose

No pediatric specific dosing recommendations are currently available. Based upon available pharmacokinetic/pharmacodynamic data in adults, dose adjustment is warranted.

No pediatric specific dosing recommendations are currently available.

For Pediatric patients: restricted to use by Pediatric Infectious Diseases Service approval.

General Information

  • Hypersensitivity

  • GI effects

  • C. difficile

  • Seizures (especially with high doses or doses not adjusted for renal function)


  • CBC, CMP weekly


  • Hypersensitivity

  • GI effects

  • Seizures (rare)

Antimicrobial class: Carbapenem

Pregnancy category: B

Average serum half life: 4 hours

Biliary penetration: Moderate

Lung penetration: Therapeutic

Urine penetration: Therapeutic

  • Mild to moderate intra-abdominal infections (biliary tract infections, diverticulitis, secondary peritonitis/GI perforation)

  • Moderate diabetic foot infections

  • Moderate surgical-site infections following contaminated procedures

  • Urinary tract infections caused by ESBL-producing organisms

  • Pyelonephritis due to ESBL-producing organisms

  • Outpatient antibiotic therapy for patients requiring IV antibiotics for polymicrobial infections caused by susceptible organisms

  • Infections in which Pseudomonas spp. or Acinetobacter spp. are suspected

Targeted therapy of ESBL infections and other resistant gram negative infections

Empiric therapy when broad spectrum of carbapenems is desired without the need for antipseudomonal activity